linjc16/ctgov huggingface dataset:
Correlation Analysis Between Rotator Cuff Tear and the Superior Migration of Humeral Head

Study Overview
=================
Brief Summary
-----------------
To evaluate the association between rotator cuff tear and the proximal migration of humeral head

Detailed Description
-----------------
In this research, 60 patients with unilateral rotator cuff tear in Peking University People's Hospital in 2018 are planned to be recruited .They will receive Magnetic Resonance Imaging(MRI) and X-ray of the painful shoulder before enrollment in this study, the duration between the two examinations was no longer than 1 week, also there is no past history of surgery in the selected shoulders. There is no other exclusion criteria. Upward Migration Index(UMI) is the ratio between the distance of humeral head center to the lower surface of acromion, and the radius of humeral head circle. It can help to minimize the effect of anatomy difference and imaging magnification, compared with the traditional acromiohumeral distance(AHD). Then we use the Spearman correlation analysis to evaluate the relationship between UMI and fatty degeneration, rotator cuff tear size and the thickness of ruptured supraspinatus tendon from X-ray and MRI.

Official Title
-----------------
Correlation Analysis Between Rotator Cuff Tear and the Superior Migration of Humeral Head

Conditions
-----------------
Rotator Cuff Tear

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient receive Magnetic Resonance Imaging half year before enrollment, showing supraspinatus tear Patient receive X-ray half year before enrollment the duration between the two examinations was no longer than 1 week no past history of surgery in the selected shoulders Exclusion criteria: patients who cannot receive MRI.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cuff tear patients<br>Patients with cuff tear | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between rotator cuff tear size and the superior migration of humeral head | Correlation between rotator cuff tear size and the superior migration of humeral head | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between rotator cuff fatty degeneration and the superior migration | Correlation between rotator cuff fatty degeneration and the superior migration | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rotator Cuff Tear, Magnetic Resonance Imaging, humeral migration
HBV Envelope Proteins Variability on HBs Antigen Clearance Under Nucleos(t)Ide Analogue Therapy

Study Overview
=================
Brief Summary
-----------------
Hepatitis B virus (HBV) infection remains difficult to eradicate with about 240 million people living with HBV chronic infection. HBsAg clearance, correlated with a good clinical prognosis, is difficult to achieve even with antiviral treatments (3-14 %). HBV envelope proteins are essential for entry into hepatocyte and are targeted by the immune system. Molecular characteristics of HBV envelope proteins may favour better viral fitness at the entry step into hepatocytes and/or HBV escape from host immunity. Here we investigated whether variability of HBV envelope proteins can contribute to the differential responses to anti-HBV treatment in patients with HBsAg clearance or persistence.

Detailed Description
-----------------
Our study is a retrospective study of patients with chronic hepatitis B virus, selected exclusively at the University Hospital Center of Nancy in the Department of Hepato-Gastroenterology (HGE). the patient inclusion criteria were as follows: Adult patients with chronic hepatitis B, treated with nucleos(t)ide analogues, mono-infected with HBV (without co-infection with HCV, HIV and HDV). For each patient included, biological, clinical and therapeutic data were collected retrospectively. Patients with loss of viral load on treatment were included in this study. Among them, patients showed either a clearance of HBsAg on treatment (responders) or the control patients showed a persistence of HBsAg on treatment (non-responders, control patients).

Official Title
-----------------
Influence of Hepatitis B Virus (HBV) Envelope Glycoprotein Characteristics on HBsAg Clearance on Anti-HBV Treatment by Nucleos(t)Ide Analogues

Conditions
-----------------
Hepatitis B, Chronic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults patients with chronic hepatitis B treated with nucleos(t)ide analogues mono-infected with HBV (without co-infection with HCV, HIV and HDV) Exclusion Criteria: minor pregnant women patients with VHC or VHD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clearance of Hepatitis B surface antigen (HBsAg) | Subgroup of patients infected by HBV genotype D | May 2016 (manuscript Velay et al., 2016) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clearance of Hepatitis B surface antigen (HBsAg) | Subgroup of patients infected by HBV genotype A | September 2017 (manuscript Eschlimann et al., 2017) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hepatitis B virus, PreS/S variability, Anti-HBV treatment
Modified Open Intraperitoneal Mesh Technique of Incisional Ventral Hernia Repair

Study Overview
=================
Brief Summary
-----------------
Ventral hernias, primary and recurrent, are major surgical challenge. We aim to investigate efficacy of modified technique of ventral hernias repair: an open intraperitoneal mesh technique.

Official Title
-----------------
Modified Open Intraperitoneal Mesh Technique of Incisional Ventral Hernia Repair

Conditions
-----------------
Incisional Ventral Hernia, Recurrent Ventral Hernia

Intervention / Treatment
-----------------
* Procedure: modified open mesh technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients aged 18 years or older American Society of Anesthesiologists physical status I, II, III Exclusion Criteria: refusal of the patients to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: modified open mesh technique<br>We performed an open intraperitoneal mesh technique in all patients: we placed surgical mesh of appropriate size intraperitoneally with transfascial fixation and drainage. | Procedure: modified open mesh technique<br>* We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.<br>* Other names: VycrilTM,2-0 resorbing sutures;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number/frequency of early postoperative complications (wound infections, seroma, hematoma) |  | four weeks after the surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative hernia recurrence |  | up to 36 months after the surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ventral hernia, infection, hematoma, seroma, recurrence, mesh technique
Scandinavian Mirena Insertion Nulliparous Trial.

Study Overview
=================
Brief Summary
-----------------
In this non-interventional study we investigate the nulliparous women individual evaluation of the insertion procedure of LNG-IUD and the follow-up period of 3 months post insertion.

Official Title
-----------------
Scandinavian Mirena Insertion Nulliparous Trial of an Observational Study.

Conditions
-----------------
Nulliparous

Intervention / Treatment
-----------------
* Drug: Mirena (BAY86-5028)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Nulliparous women Mirena insertion planned as contraceptive method Exclusion Criteria: Ongoing or suspected pregnancy; Ongoing or recidivating genital infection; Cervicitis; Cervical dysplasia; Malignancy in uterus or cervix; Confirmed or suspected hormone sensitive neoplasia including breast cancer Undiagnosed abnormal uterine bleeding; Uterine anomaly including myoma if the cavity of the uterus is restricted; Conditions that cause increased risk of infections; Acute liver disease or liver tumour; Allergy to the active substance or any component of the IUD

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Arm 1<br> | Drug: Mirena (BAY86-5028)<br>* Nulliparous Women<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the insertion procedure of Mirena in nulliparous women |  | At the insertion time point | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain |  | At the insertion time point | 
| Continuation rate |  | 12-16 weeks post insertion | 
| Bleeding Pattern |  | 12-16 weeks post insertion | 
| Satisfaction |  | 12-16 weeks post insertion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mirena, Nulliparous, Intrauterine Devices
Continuous Versus Intermittent Oxytocin for Induction of Labor: A Randomized Study

Study Overview
=================
Brief Summary
-----------------
This study evaluates continuous oxytocin versus intermittent oxytocin for induction of labor at term. Half of participants will be taken continuous oxytocin, while the other half will be taken intermittent oxytocin.

Detailed Description
-----------------
In the continuous oxytocin group, traditional treatment of oxytocin used at a starting dose of 1-2 mIU/min and the dose was increased by 2 mIU/min at every 15 minutes until regular contractions obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin was 40 mIU/min and oxytocin was administered until delivery. In the intermittent group, oxytocin was discontinued when cervical dilation was 5 cm and 2 hours after discontinuation oxytocin was reused at a starting dose of 1-2 mIU/min and was increased as the same protocol used for continuation oxytocin group.

Conditions
-----------------
Intemittant, Continue, Oxytocin

Intervention / Treatment
-----------------
* Drug: Oxytocin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: singleton pregnancy, 37≤ weeks of gestational age , vertex presentation, women with cervical dilation 3 cm no contraindication to vaginal delivery. Exclusion Criteria: fetal malpresentation, multifetal pregnancy, more than three contractions in 10 minutes, contraindications to oxytocin, a category II or III fetal heart rate pattern, fetal anomaly, fetal demise women with immediate delivery indications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Continuous oxytocin<br>oxytocin will be used at a starting dose of 1-2 mIU/min and the dose will be increased by 2 mIU/min at every 15 minutes until regular contractions will be obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin will 40 mIU/min and oxytocin will be administered until delivery. | Drug: Oxytocin<br> <br> |
| Experimental: intermittent oxytocin<br>oxytocin will be discontinued when cervical dilation will 5 cm and 2 hours after discontinuation oxytocin will be reused at a starting dose of 1-2 mIU/min and will be increased as the same protocol will be used for continuation oxytocin group. | Drug: Oxytocin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| induction-to-delivery time |  | intraoperative |
Effectiveness of Intratympanic Dexamethasone With Ligmocaine for Alleviation of Tinnitus

Study Overview
=================
Brief Summary
-----------------
Objective: To determine the effectiveness of Intratympanic dexamethasone with lignocaine in control of idiopathic tinnitus. Methodology: 264 consenting patients with idiopathic unilateral tinnitus presenting at ENT Department were assessed for tinnitus severity using Modified Tinnitus Handicap Inventory and the scores recorded and subsequently administered intratympanically 2.0 ml (milliliter's) of dexamethasone and lignocaine (1.5 ml dexamethasone + 0.5 ml 1% lignocaine). The dose was repeated twice at weekly intervals. All patients were re assessed on Modified Tinnitus Handicap Inventory two weeks after third Intratympanic administration.

Official Title
-----------------
Effectiveness of Dexamethasone With Lignocaine for Alleviation of Tinnitus

Conditions
-----------------
Tinnitus

Intervention / Treatment
-----------------
* Drug: Dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: score 20 or above on modified tinnitus handicap inventory Exclusion Criteria: head trauma, tympanic membrane perforation, depression, ear surgery

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dexamethasone with lignocaine<br> | Drug: Dexamethasone<br>* Steroids and analgesics<br>* Other names: Lignocaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tinnitus relief | Tinnitus relief ascertained by Modified Tinnitus Handicap Inventory | 2 weeks |
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia

Study Overview
=================
Brief Summary
-----------------
To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.

Official Title
-----------------
A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia

Conditions
-----------------
Community-Acquired Infections, Bacterial Pneumonia, Cross Infection

Intervention / Treatment
-----------------
* Drug: Tigecycline
* Drug: Levofloxacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female subjects ≥ 18 years of age and in Bulgaria only ≤ 70 years of age Subjects hospitalized with CAP with a severity that requires IV antibiotic treatment for at least 7 days The presence of fever (within 24 hours before randomization) Exclusion Criteria: Any concomitant condition that, in the opinion of the investigator, would preclude an evaluation of a response or make it unlikely that the contemplated course of therapy could be completed (eg, life expectancy <30 days). Hospitalization within 14 days before the onset of symptoms. Residence in a long-term care facility or nursing home ≥14 days before the onset of symptoms.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tigecycline|nan|
|Drug: Levofloxacin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical response in the clinically evaluable population and the clinical modified intent-to-treat population at the TOC visit. |  |  | 
| Determine whether tigecycline is noninferior to levofloxacin. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bacterial Pneumonia
Endometrial Nerve Fibers Detection in Patients With Different Gynecological Pathologies

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the prevelence of endometrial nerve fibers in different gynecological pathologies

Detailed Description
-----------------
The aim of this study is to investigate the prevelence of endometrial nerve fibers in different gynecological pathologies in addition to its relation to chronic pelvic pain

Official Title
-----------------
Endometrial Nerve Fibers Detection in Patients With Different Gynecological Pathologies

Conditions
-----------------
Gynecological Pathologies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 20-60 years of age. Written and signed informed consent by the patient to participate in the study. Women candidate for surgical intervention either via laparoscopy or laparotomy for different gynecological pathologies Exclusion Criteria: Suspected endometriosis. Patient unwillingness to participate in the study. No hormonal treatment for the last 6 months. Suspected pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevelencce of endometrial nerve fibers | Is to determine the prevelence of endometrial nerve fibers in different gynecological pathologies I via endometrial sampling | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pelvic pain | Relating the density of endometrial nerve fibres to different types of pelvic pain | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometrial nerve fibres
Ertapenem in Patients With Urosepsis

Study Overview
=================
Brief Summary
-----------------
Ertapenem, a broad-spectrum carbapenem antibiotic, has shown promising in vitro activity agenst ESBL-producing Enterobacteriacae. This agent was licensed in United State of America and Europe for several clinical use in complicated intraabdominal infections, complicated skin and skin-structure infections, acute pelvic infections, complicated urinary tract infections and community-acquired pneumonia. In common with other beta-lactams, ertapenem exhibits primarily time-dependent activity, and the percentage of the exposure time during which the free drug concentration remain above the MIC (%T>MIC) is the pharmacokinetic/pharmacodynamics (PK/PD) index that best correlates with efficacy. Pathophysiological changes in critically ill patients with severe infections resulting in altered PK patterns that may affect therapeutic plasma concentrations and achievement of PD have been found with several antimicrobial agents. The aim of the study was to determine the PK of ertapenem in patients with urosepsis.

Official Title
-----------------
Pharmacodynamics of Ertapenem in Patients With Urosepsis

Conditions
-----------------
Patients With Urosepis and Received Ertapenem for Treatment

Intervention / Treatment
-----------------
* Drug: Ertapenem Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >18 years of age Diagnosis of urosepsis Exclusion Criteria: They were pregnant Circulatory shock (defined as a systolic blood pressure of < 90 mmHg and pour tissue perfusion) Documented hypersensitivity to carbapenems Estimated creatinine clearance (CLcr) (determined by the Crockcroft-Goult method) of < 30 mL/min

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ertapenem in urosepsis<br>Ertapenem PK studies were carried out on the 3rd dose of ertapenem administration. Blood samples (3 mL) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the start of ertapenem administration. All blood samples were added to a heparinized tube and centrifuged at 1,000 g for 10 min at 4°C within 5 min. | Drug: Ertapenem Injection<br>* 1 g of ertapenem q24h, 30 min infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of ertapenem in plasma |  | 48 hours after the ertapenem dose | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pharmacokinetic, pharmacodynamic, ertapenem, urosepsis